Literature DB >> 15717039

Evidence from clinical trials: can we do better?

Andrew D Siderowf1.   

Abstract

Randomized clinical trials provide the most internally valid evidence for medical decision-making. In many areas of neurology, results from clinical trials showing which therapies are and are not effective have had a substantial impact on patient care. Relative to observational methods, the central advantage of clinical trials is control of bias attributable to unmeasured differences between patients. However, trials also have clear limitations, including a historical failure to include a representative cross-section of patients with a given disease, and highly structured treatment regimes that are difficult to replicate in normal practice settings. These limitations tend to reduce the generalizability of results from clinical trials. This article reviews some ways in which the design and application of clinical trials could be improved so that the evidence produced would be more relevant to health-care providers and other decision makers.

Entities:  

Mesh:

Year:  2004        PMID: 15717039      PMCID: PMC534941          DOI: 10.1602/neurorx.1.3.363

Source DB:  PubMed          Journal:  NeuroRx        ISSN: 1545-5343


  72 in total

1.  The ethical problems with sham surgery in clinical research.

Authors:  R Macklin
Journal:  N Engl J Med       Date:  1999-09-23       Impact factor: 91.245

2.  Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease.

Authors:  T B Freeman; D E Vawter; P E Leaverton; J H Godbold; R A Hauser; C G Goetz; C W Olanow
Journal:  N Engl J Med       Date:  1999-09-23       Impact factor: 91.245

3.  The multicenter study of epilepsy surgery: recruitment and selection for surgery.

Authors:  Anne T Berg; Barbara G Vickrey; John T Langfitt; Michael R Sperling; Thaddeus S Walczak; Shlomo Shinnar; Carl W Bazil; Steven V Pacia; Susan S Spencer
Journal:  Epilepsia       Date:  2003-11       Impact factor: 5.864

Review 4.  Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials.

Authors:  Gordon C S Smith; Jill P Pell
Journal:  BMJ       Date:  2003-12-20

5.  Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.

Authors:  Sean R Tunis; Daniel B Stryer; Carolyn M Clancy
Journal:  JAMA       Date:  2003-09-24       Impact factor: 56.272

6.  The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993.

Authors:  R Mayeux; K Marder; L J Cote; J Denaro; N Hemenegildo; H Mejia; M X Tang; R Lantigua; D Wilder; B Gurland
Journal:  Am J Epidemiol       Date:  1995-10-15       Impact factor: 4.897

7.  Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.

Authors:  Garnet L Anderson; Howard L Judd; Andrew M Kaunitz; David H Barad; Shirley A A Beresford; Mary Pettinger; James Liu; S Gene McNeeley; Ana Maria Lopez
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

Review 8.  Stroke.

Authors:  Charles Warlow; Cathie Sudlow; Martin Dennis; Joanna Wardlaw; Peter Sandercock
Journal:  Lancet       Date:  2003-10-11       Impact factor: 79.321

9.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

Authors:  Christopher M Clark; Sharon Xie; Jesse Chittams; Douglas Ewbank; Elaine Peskind; Douglas Galasko; John C Morris; Daniel W McKeel; Martin Farlow; Sharon L Weitlauf; Joseph Quinn; Jeffrey Kaye; David Knopman; Hiroyuki Arai; Rachelle S Doody; Charles DeCarli; Susan Leight; Virginia M-Y Lee; John Q Trojanowski
Journal:  Arch Neurol       Date:  2003-12

10.  Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease.

Authors:  T B Freeman; C W Olanow; R A Hauser; G M Nauert; D A Smith; C V Borlongan; P R Sanberg; D A Holt; J H Kordower; F J Vingerhoets
Journal:  Ann Neurol       Date:  1995-09       Impact factor: 10.422

View more
  5 in total

1.  Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.

Authors:  Stefan Willmann; Liping Zhang; Hannah Mayer; Hans-Ulrich Siegmund; Takahiko Tanigawa; Masato Kaneko; Gary Peters; Jeffrey I Weitz; Scott D Berkowitz; Rolf Burghaus
Journal:  Blood Adv       Date:  2018-11-27

2.  Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group.

Authors:  Lillian Sung; Richard Aplenc; Todd A Alonzo; Robert B Gerbing; Thomas Lehrnbecher; Alan S Gamis
Journal:  Blood       Date:  2013-03-07       Impact factor: 22.113

3.  Generalizability in two clinical trials of Lyme disease.

Authors:  Daniel J Cameron
Journal:  Epidemiol Perspect Innov       Date:  2006-10-17

4.  Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus.

Authors:  Xiaoling Cai; Linong Ji
Journal:  Diabetes Ther       Date:  2021-05-28       Impact factor: 2.945

5.  Assessing the external validity of a randomized controlled trial of anthelminthics in mothers and their children in Entebbe, Uganda.

Authors:  James D Millard; Lawrence Muhangi; Moses Sewankambo; Juliet Ndibazza; Alison M Elliott; Emily L Webb
Journal:  Trials       Date:  2014-08-06       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.